Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer

William M. Hilton, Barbara Ercole, Dipen J Parekh, Guru Sonpavde, Rita Ghosh, Robert S. Svatek

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Intravesical immunotherapy using attenuated bacillus Calmette-Guérin (BCG) strains and intravesical chemotherapy are the modalities most commonly used to treat intermediate- or high-risk patients with non-muscle invasive bladder cancer. BCG has been shown to decrease recurrence rates by up to 67% compared with tumor resection alone, but intensive BCG maintenance regimens are poorly tolerated in a large proportion of patients. Intravesical chemotherapy also decreases the risk of recurrence for these patients, but has diminished efficacy compared with BCG. If BCG dose reduction can be achieved with combined intravesical immunotherapy and chemotherapy, this regimen may improve compliance and thus optimize treatment for these patients by limiting side effects from BCG monotherapy, while at the same time improving oncologic efficacy via the separate anti-tumor mechanisms of these agents. The authors discuss the most recent data regarding combining these agents in an alternating or sequential regimen.

Original languageEnglish
Pages (from-to)949-957
Number of pages9
JournalExpert Review of Anticancer Therapy
Volume11
Issue number6
DOIs
StatePublished - Jun 1 2011
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Immunotherapy
Bacillus
Drug Therapy
Recurrence
Compliance
Neoplasms
Maintenance

Keywords

  • bacillus Calmette-Guérin
  • intravesical therapy
  • mitomycin C
  • non-muscle invasive bladder cancer

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer. / Hilton, William M.; Ercole, Barbara; Parekh, Dipen J; Sonpavde, Guru; Ghosh, Rita; Svatek, Robert S.

In: Expert Review of Anticancer Therapy, Vol. 11, No. 6, 01.06.2011, p. 949-957.

Research output: Contribution to journalArticle

Hilton, William M. ; Ercole, Barbara ; Parekh, Dipen J ; Sonpavde, Guru ; Ghosh, Rita ; Svatek, Robert S. / Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer. In: Expert Review of Anticancer Therapy. 2011 ; Vol. 11, No. 6. pp. 949-957.
@article{f7818afac4a044b5b4a3b9a60a93470a,
title = "Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer",
abstract = "Intravesical immunotherapy using attenuated bacillus Calmette-Gu{\'e}rin (BCG) strains and intravesical chemotherapy are the modalities most commonly used to treat intermediate- or high-risk patients with non-muscle invasive bladder cancer. BCG has been shown to decrease recurrence rates by up to 67{\%} compared with tumor resection alone, but intensive BCG maintenance regimens are poorly tolerated in a large proportion of patients. Intravesical chemotherapy also decreases the risk of recurrence for these patients, but has diminished efficacy compared with BCG. If BCG dose reduction can be achieved with combined intravesical immunotherapy and chemotherapy, this regimen may improve compliance and thus optimize treatment for these patients by limiting side effects from BCG monotherapy, while at the same time improving oncologic efficacy via the separate anti-tumor mechanisms of these agents. The authors discuss the most recent data regarding combining these agents in an alternating or sequential regimen.",
keywords = "bacillus Calmette-Gu{\'e}rin, intravesical therapy, mitomycin C, non-muscle invasive bladder cancer",
author = "Hilton, {William M.} and Barbara Ercole and Parekh, {Dipen J} and Guru Sonpavde and Rita Ghosh and Svatek, {Robert S.}",
year = "2011",
month = "6",
day = "1",
doi = "10.1586/era.11.69",
language = "English",
volume = "11",
pages = "949--957",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer

AU - Hilton, William M.

AU - Ercole, Barbara

AU - Parekh, Dipen J

AU - Sonpavde, Guru

AU - Ghosh, Rita

AU - Svatek, Robert S.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Intravesical immunotherapy using attenuated bacillus Calmette-Guérin (BCG) strains and intravesical chemotherapy are the modalities most commonly used to treat intermediate- or high-risk patients with non-muscle invasive bladder cancer. BCG has been shown to decrease recurrence rates by up to 67% compared with tumor resection alone, but intensive BCG maintenance regimens are poorly tolerated in a large proportion of patients. Intravesical chemotherapy also decreases the risk of recurrence for these patients, but has diminished efficacy compared with BCG. If BCG dose reduction can be achieved with combined intravesical immunotherapy and chemotherapy, this regimen may improve compliance and thus optimize treatment for these patients by limiting side effects from BCG monotherapy, while at the same time improving oncologic efficacy via the separate anti-tumor mechanisms of these agents. The authors discuss the most recent data regarding combining these agents in an alternating or sequential regimen.

AB - Intravesical immunotherapy using attenuated bacillus Calmette-Guérin (BCG) strains and intravesical chemotherapy are the modalities most commonly used to treat intermediate- or high-risk patients with non-muscle invasive bladder cancer. BCG has been shown to decrease recurrence rates by up to 67% compared with tumor resection alone, but intensive BCG maintenance regimens are poorly tolerated in a large proportion of patients. Intravesical chemotherapy also decreases the risk of recurrence for these patients, but has diminished efficacy compared with BCG. If BCG dose reduction can be achieved with combined intravesical immunotherapy and chemotherapy, this regimen may improve compliance and thus optimize treatment for these patients by limiting side effects from BCG monotherapy, while at the same time improving oncologic efficacy via the separate anti-tumor mechanisms of these agents. The authors discuss the most recent data regarding combining these agents in an alternating or sequential regimen.

KW - bacillus Calmette-Guérin

KW - intravesical therapy

KW - mitomycin C

KW - non-muscle invasive bladder cancer

UR - http://www.scopus.com/inward/record.url?scp=79959783271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959783271&partnerID=8YFLogxK

U2 - 10.1586/era.11.69

DO - 10.1586/era.11.69

M3 - Article

VL - 11

SP - 949

EP - 957

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 6

ER -